Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on January 20, 2026. The filing addresses a change in senior management effective as of the report date.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure: Donald Notman, Chief Financial Officer (CFO) and Chief Operating Officer (COO), is taking a temporary medical leave of absence effective January 20, 2026.
- Appointment: Jason Robins, Senior Vice President, Finance, was appointed as Interim CFO, Principal Financial Officer, and Principal Accounting Officer effective January 20, 2026.
- Compensation: Mr. Robins was granted an option to purchase 33,000 shares of common stock at an exercise price of $11.45 per share. The options vest in equal monthly installments over four years.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The only disclosed contingency is the potential indemnification obligation for Mr. Robins under the Company's standard Indemnification Agreement, which may require the Company to cover legal expenses, judgments, fines, or settlement amounts arising from his service.
Investor Verification Checklist
- Verify the anticipated return date for Donald Notman from medical leave.
- Confirm the total number of shares reserved under the 2021 Stock Incentive Plan and the impact of the new grant on dilution.
- Review the terms of the Indemnification Agreement filed as Exhibit 10.12 to the S-1 Registration Statement.
- Monitor subsequent filings for any updates regarding the duration of the interim CFO arrangement.